High-Dose IV Vitamin C in Sepsis and Critical Illness

What is established

Intravenous administration of vitamin C is a well-characterized, low-risk procedure. Giving vitamin C by IV rather than orally bypasses gut absorption limits and produces much higher blood concentrations than any oral dose can achieve. That pharmacological fact is not in dispute and is not what this review is about.

What is not established is that this higher blood concentration changes outcomes in critically ill or septic patients. The idea gained traction from a rationale that grew out of small pilot studies and case series suggesting vitamin C might support blood vessel function, reduce inflammatory injury, and help support blood pressure in sepsis. That mechanistic story is plausible on paper. It has not translated into a demonstrated survival or recovery benefit in the largest, best-conducted trial built to test it.[1]

What the evidence for this specific use actually shows

The LOVIT trial, published in the New England Journal of Medicine in 2022, is the largest and most rigorous randomized trial of high-dose IV vitamin C in sepsis to date. It enrolled 872 adults with sepsis requiring vasopressor support in the ICU and randomized them to high-dose IV vitamin C or placebo. The result ran counter to the earlier hope: patients who received vitamin C had a higher composite rate of death or persistent organ dysfunction at 28 days than those who received placebo, 44.5 percent versus 38.5 percent, a relative risk of 1.21 in favor of harm rather than benefit.[1]

Set against that, a 2023 systematic review and meta-analysis pooling 16 randomized trials of IV vitamin C monotherapy in critically ill patients, just over 2,100 patients in total, found the opposite direction of effect: a reduced overall mortality with a relative risk of 0.73. Taken alone, that looks like a positive signal worth pursuing.[2]

The two results cannot both be treated as equally reliable, and they should not be averaged into a comfortable middle position. LOVIT is a single, large, blinded, placebo-controlled trial purpose-built to answer this exact question, with a prespecified composite outcome and adequate statistical power. The meta-analysis pools 16 smaller and more heterogeneous trials, many of them older, smaller, and not all conducted with the same rigor, and its own authors rated the certainty of evidence as low. When a large, well-conducted trial disagrees with a pooled analysis of smaller, lower-quality trials, standard evidence hierarchy gives more weight to the large trial, not less.[1][2]

The trap: a meta-analysis is not automatically the strongest evidence

It is tempting to treat a systematic review pooling 16 trials as automatically more authoritative than any single trial, on the reasoning that more studies means more evidence. That reasoning breaks down when the pooled trials are individually small, methodologically inconsistent, and rated as low-certainty by the reviewers doing the pooling. A meta-analysis is only as strong as the trials that feed it. Pooling underpowered, heterogeneous studies can produce a confident-looking summary number that does not survive contact with one adequately powered trial designed to settle the question directly.[2]

What remains uncertain, and the negative finding that should not be minimized

LOVIT's composite primary outcome result was noted by its own authors to be statistically fragile under alternate analytic adjustments, and mortality analyzed on its own was not significantly different between groups. This is worth stating plainly rather than glossing over: the trial does not prove that vitamin C definitively kills septic patients. What it does show, clearly, is that high-dose IV vitamin C failed to demonstrate the benefit that smaller studies had suggested, in the one trial built with enough patients and rigor to test that claim properly, and the point estimate leaned toward harm rather than neutrality.[1]

It also remains uncertain whether some subgroup of critically ill patients, at some different dose, timing, or combination with other agents, might respond differently. No adequately powered trial has established such a subgroup, and proposing one without evidence would be speculation, not a clinical recommendation.

What this means for you

AION does not offer IV vitamin C as a treatment for sepsis or critical illness, and this evidence review is a reason why. Sepsis and critical illness are managed in hospital intensive care units, with vasopressor support, source control, and antibiotics decided by the treating physician team, not in an outpatient wellness setting. Any patient presenting to AION with signs of serious infection, high fever with confusion, low blood pressure, or rapid deterioration is directed to emergency care, not to an infusion chair.

Where AION does offer IV vitamin C, it is positioned as a nutrient-repletion and wellness therapy for appropriately screened patients, with diagnostics and physician judgment determining eligibility, not a fixed protocol applied to everyone who asks for it. This review lays out the actual state of the data, including the large trial that argues against extending this therapy into critical illness, so you and your own physician can see it plainly rather than a marketing summary that only cites the studies that look favorable.